The translational gap for gene therapies in low- and middle-income countries
Issued Date
2024-05-08
Resource Type
eISSN
19466242
Scopus ID
2-s2.0-85192633925
Pubmed ID
38718130
Journal Title
Science translational medicine
Volume
16
Issue
746
Rights Holder(s)
SCOPUS
Bibliographic Citation
Science translational medicine Vol.16 No.746 (2024) , eadn1902
Suggested Citation
Doxzen K.W., Adair J.E., Bazzo Y.M.F., Bukini D., Cornetta K., Dalal V., Guerino-Cunha R.L., Hongeng S., Jotwani G., Kityo-Mutuluuza C., Lakshmanan K., Mahlangu J., Makani J., Mathews V., Ozelo M.C., Rangarajan S., Scholefield J., Júnior J.B.S., McCune J.M. The translational gap for gene therapies in low- and middle-income countries. Science translational medicine Vol.16 No.746 (2024) , eadn1902. doi:10.1126/scitranslmed.adn1902 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98372
Title
The translational gap for gene therapies in low- and middle-income countries
Author's Affiliation
Fred Hutchinson Cancer Center
Agência Nacional de Vigilância Sanitária, Brazil
Muhimbili University of Health and Allied Sciences
University of the Witwatersrand Faculty of Health Sciences
Joint Clinical Research Center Uganda
Ministry of Health and Family Welfare
Universidade Estadual de Campinas
Indian Council of Medical Research
University of Southampton, Faculty of Medicine
Universidade de Brasília
Bill & Melinda Gates Foundation
Indiana University School of Medicine
Yale School of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
University of Washington
Imperial College London
The Council for Scientific and Industrial Research
Faculty of Health Sciences
Christian Medical College, Vellore
Haematology & Rare Disorders (ACOHRD)
RJ
Centro Paulista de Oncologia
Strategic Analysis, Inc.
Agência Nacional de Vigilância Sanitária, Brazil
Muhimbili University of Health and Allied Sciences
University of the Witwatersrand Faculty of Health Sciences
Joint Clinical Research Center Uganda
Ministry of Health and Family Welfare
Universidade Estadual de Campinas
Indian Council of Medical Research
University of Southampton, Faculty of Medicine
Universidade de Brasília
Bill & Melinda Gates Foundation
Indiana University School of Medicine
Yale School of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
University of Washington
Imperial College London
The Council for Scientific and Industrial Research
Faculty of Health Sciences
Christian Medical College, Vellore
Haematology & Rare Disorders (ACOHRD)
RJ
Centro Paulista de Oncologia
Strategic Analysis, Inc.
Corresponding Author(s)
Other Contributor(s)
Abstract
Gene therapies are designed to address the root cause of disease. As scientific understanding of disease prevention, diagnosis, and treatment improves in tandem with technological innovation, gene therapies have the potential to become safe and effective treatment options for a wide range of genetic and nongenetic diseases. However, as the medical scope of gene therapies expands, consideration must be given to those who will benefit and what proactive steps must be taken to widen development and access potential, particularly in regions carrying a high disease burden.